drugset

drugset / Trial / NCT00664742

The Effect of Fluvastatin XL® Treatment in Patients With Metabolic Syndrome

NCT00664742 ↗

Phase 4 Completed 614 enrolled Novartis

NaSingle-groupOpen-labelTreatment

Summary

This study evaluated safety, tolerability and efficacy of Fluvastatin XL® -extended release (80 mg once daily) in patients with metabolic syndrome

Timeline

Start: 2006-09
Primary completion: 2007-10
Completion: 2007-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Fluvastatin	Other / unclassified	80 mg	—

Indications